Brand Name

Lonsurf

Generic Name
Trifluridine
View Brand Information
FDA approval date: May 14, 2001
Classification: Nucleoside Metabolic Inhibitor
Form: Tablet, Solution

What is Lonsurf (Trifluridine)?

LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Who is this study for: Patients with Colorectal Cancer
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Combination product, Diagnostic test
Study Drugs: TAS-102, Irinotecan, Standard Treatment
Study Phase: Phase 1

Summary: This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).
Enrollment Status: Recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: Primary Objectives * In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®) * In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) Secondary Objectives * To evaluate disease control rate (DCR) * To evalu...

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

View All Clinical Trials

Related Latest Advances

Trifluridine-Tipiracil with and without Bevacizumab in Colorectal Cancer.
Trifluridine-Tipiracil with and without Bevacizumab in Colorectal Cancer.
Journal: NEJM evidence
Published: February 24, 2026
Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence?
Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence?
Journal: Clinical advances in hematology & oncology : H&O
Published: February 20, 2026
Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab.
Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
View All Latest Advances